← Ecuador

Ecuador edition

English - Ecuador Priority Conditions Packet

Education only: no diagnosis, dosing or drug-interaction advice. Always consult a clinician.

Cover of English - Ecuador Priority Conditions Packet
English
New

$19

  • 14 pages
  • 67 numbered sources
  • Unranked
  • English edition

What published research does and does not show for ten conditions relevant to Ecuador, unranked because no national data on reasons for use were found: the six uses named in Acuerdo Ministerial 00148-2021 (refractory epilepsy, MS spasticity and pain, cancer pain, chemotherapy nausea and vomiting, anorexia-cachexia, chronic non-cancer pain) and four regional conditions from Argentina’s survey (sleep, anxiety, depression, migraine), each labelled. Plain evidence-strength labels, cautions for all ten, Ecuadorian legal context (COIP Art. 220, AM 00148-2021) and patient handoff sheets.

Written for Ecuador. The ten conditions are not ranked; each gets a plain evidence label, and nothing here says cannabis cures them. Education only: no doses, no product recommendations, no drug-interaction verdicts. For the law, check official government sources.

Get it on Payhip ↗ More for Ecuador

Checkout and download happen on Payhip, our store. Questions before you buy? Email [email protected].

Patient or caregiver? Start with our page for you.

What this packet covers

Ten conditions relevant to Ecuador, NOT ranked: no national data on why people in Ecuador use cannabis were found. Six are the uses named in Ecuador’s 2021 medical cannabis regulation and four are regional conditions from neighbouring Argentina’s survey, each labelled. Each summary gives the evidence-strength label the packet assigns, why the condition is included, its key cautions and the number of sources it cites for that condition.

How the packet labels evidence strength

  • Some human evidence randomized trials suggest a benefit for the condition or a key symptom, usually small
  • Mixed trials conflict, are very small, or show benefit on some outcomes but not others
  • Little or none controlled trials found no benefit, or only case reports and observational data exist

Bottom line from the packet

Being named in Ecuador’s regulation does not mean the evidence is strong. Among the ten, the clearest trial results are for prescription cannabidiol in specific rare epilepsies, chemotherapy nausea, patient-rated MS spasticity and small average benefits in chronic, mainly neuropathic, pain. Cancer pain trials were negative, and the regional conditions (sleep, anxiety, depression) have weak or mixed evidence; migraine has one promising acute trial. The harm evidence (psychosis, use disorder, hyperemesis, driving) applies to all ten.

Refractory epilepsy and MS spasticity

Refractory epilepsy

Evidence strength: Some human evidence (prescription CBD, specific syndromes)

Why it is included
Named in Ecuador’s 2021 regulation (Acuerdo Ministerial 00148-2021, Art. 4, adjuvant cannabidiol). Named does not mean the trial evidence is strong.
What the research shows
The National Academies (2017) conclusion of insufficient evidence predates the main trials. Added to existing seizure medicines, prescription cannabidiol reduced convulsive seizures in Dravet syndrome, drop seizures in Lennox-Gastaut syndrome in two trials and seizures in tuberous sclerosis complex; a 2019 review found that cannabidiol probably reduces seizure frequency in children with drug-resistant epilepsy. These results apply to the purified products tested, not to cannabis in general.
Key cautions
  • Blood levels of several seizure medicines changed with cannabidiol in an expanded-access study; the authors stress monitoring levels and liver tests.
  • In tests of non-prescription CBD products, labels were often inaccurate and THC was found in 6 of 11 oils.

10 cited sources · packet refs [1, 4–12]

Spasticity and pain in multiple sclerosis

Evidence strength: Some human evidence (patient-reported)

Why it is included
Named in Ecuador’s 2021 regulation (Acuerdo Ministerial 00148-2021, Art. 5(c)). Named does not mean the trial evidence is strong.
What the research shows
The National Academies (2017) found conclusive or substantial evidence for oral cannabinoids for patient-reported MS spasticity. Cochrane (2022) found that nabiximols probably reduces the severity of spasticity in the short term; effects on neuropathic pain and quality of life are uncertain. In the CAMS trial, cannabinoids did not change the measured Ashworth score, but more patients reported less spasticity, and a 2024 crossover trial missed its primary measured-spasticity endpoint.
Key cautions
  • Cannabinoids may slightly increase stopping treatment for adverse events (Cochrane 2022).
  • In an online survey of 281 people with MS in Argentina, 34.2% were current cannabis users; 41.9% started after diagnosis, and 54.3% of these had never discussed it with their neurologist. The packet asks whether the neurologist is aware of any cannabis use.

9 cited sources · packet refs [1, 4, 13–19]

Cancer pain, chemotherapy nausea, cachexia

Moderate to severe cancer pain

Evidence strength: Little or none

Why it is included
Named in Ecuador’s 2021 regulation (Acuerdo Ministerial 00148-2021, Art. 5(e)). Named does not mean the trial evidence is strong.
What the research shows
A 2023 Cochrane review (14 studies, 1,823 participants) found moderate-certainty evidence that nabiximols or THC added to opioids gave no clinically relevant benefit in opioid-refractory cancer pain; a meta-analysis found no difference from placebo, and a phase 3 nabiximols trial missed its primary endpoint.
Key cautions
  • Somnolence was more common than with placebo in the meta-analysis.
  • ASCO (2024) recommends against cannabis or cannabinoids as a cancer-directed treatment outside a clinical trial; no evidence shows that cannabis treats cancer itself.

5 cited sources · packet refs [1, 20–22, 26]

Chemotherapy-induced nausea and vomiting

Evidence strength: Some human evidence (best of the ten)

Why it is included
Named in Ecuador’s 2021 regulation (Acuerdo Ministerial 00148-2021, Art. 5(b)). Named does not mean the trial evidence is strong.
What the research shows
The National Academies (2017) found conclusive or substantial evidence for oral cannabinoids in chemotherapy-induced nausea and vomiting, but the 23 trials in the 2015 Cochrane review date from 1975 to 1991, with no comparisons with modern antiemetics. Added to guideline antiemetics in a trial of 147 participants, oral THC:CBD raised complete response from 8% to 24%. ASCO (2024) says cannabinoids may be added for refractory chemotherapy nausea; MASCC found THC and nabilone better than placebo but not better than other antiemetics.
Key cautions
  • In the earlier phase II trial, 31% reported moderate or severe cannabinoid-related adverse events.
  • Regular use can itself cause cyclic vomiting (hyperemesis); stopping cannabis appears to be the most effective treatment.

8 cited sources · packet refs [1, 4, 23–28]

Anorexia-cachexia and palliative symptoms

Evidence strength: Mixed

Why it is included
Named in Ecuador’s 2021 regulation (Acuerdo Ministerial 00148-2021, Art. 5(a), including HIV or cancer). Named does not mean the trial evidence is strong.
What the research shows
The National Academies (2017) found limited evidence for appetite and weight loss in HIV/AIDS, and no or insufficient evidence for cancer-associated anorexia cachexia syndrome. In AIDS-related weight loss, dronabinol improved appetite (38% vs 8%). In cancer, megestrol acetate improved appetite more than dronabinol (75% vs 49%), and in 243 patients with cancer cachexia neither cannabis extract nor THC differed from placebo. A pilot trial in 47 people with lung cancer found nabilone increased caloric intake.
Key cautions
  • MASCC found no high-quality evidence to recommend cannabis for psychological symptoms in people with cancer.
  • The packet asks which cause of weight loss is being treated, and whether nutrition support has been offered.

8 cited sources · packet refs [1, 4, 26, 29–33]

Chronic non-cancer pain

Chronic non-cancer pain in adults

Evidence strength: Some human evidence (small)

Why it is included
Named in Ecuador’s 2021 regulation (Acuerdo Ministerial 00148-2021, Art. 5(d), in adults). Named does not mean the trial evidence is strong.
What the research shows
Many trials. A 2021 BMJ meta-analysis of 32 trials (5,174 patients) found a small increase in the share of patients reaching a meaningful improvement in pain; a 2026 update found small short-term improvements, mainly in neuropathic pain, with more adverse events. The 2026 Cochrane update on neuropathic pain found no clear evidence for THC-dominant medicines. In a 2025 phase 3 trial in 820 adults with chronic low back pain, a cannabis extract reduced pain by 0.6 points more than placebo on a 0–10 scale.
Key cautions
  • In a four-year cohort of 1,514 people prescribed opioids for chronic non-cancer pain, there was no evidence that cannabis use reduced pain severity or had an opioid-sparing effect.
  • The 2018 Cochrane review on neuropathic pain concluded that potential benefits might be outweighed by potential harms.

11 cited sources · packet refs [1, 4, 34–42]

Sleep, anxiety and depression (regional)

Sleep (regional)

Evidence strength: Mixed

Why it is included
Regional, not named in Ecuador’s rules: 10% of disease answers in Argentina’s RACME/CONICET survey (1,459 responses). No Ecuadorian data on reasons for use were found.
What the research shows
The National Academies (2017) found moderate evidence for short-term sleep outcomes in sleep disturbance linked to sleep apnea, fibromyalgia, chronic pain and MS. The 2026 Cochrane review found that medical cannabis may have little to no meaningful effect in insomnia (very low certainty), while a meta-analysis of 39 trials found a small improvement in sleep quality in chronic pain. Small two-week insomnia trials reported better sleep; a 2026 JAMA review says trial evidence does not support cannabis for insomnia.
Key cautions
  • In a pragmatic trial, adults given a medical cannabis card reported fewer insomnia symptoms but more cannabis use disorder symptoms.
  • The packet asks what is driving the poor sleep (pain, anxiety, sleep apnea, shift work, alcohol) and whether cognitive behavioural therapy for insomnia has been offered.

9 cited sources · packet refs [3, 4, 43–49]

Anxiety (regional)

Evidence strength: Mixed

Why it is included
Regional, not named in Ecuador’s rules: 7% of disease answers in Argentina’s RACME/CONICET survey (1,459 responses). No Ecuadorian data on reasons for use were found.
What the research shows
The National Academies (2017) found limited evidence for cannabidiol in a public speaking test in social anxiety disorders. A 2019 Lancet Psychiatry review found very low-quality evidence of slight improvement with pharmaceutical THC; a 2026 update of 54 trials found no significant effect on anxiety. A 2024 meta-analysis of cannabidiol (316 participants) found a large effect but urged caution because of small samples, and a 2025 review found a high risk of bias. In 50 women with advanced breast cancer, cannabidiol missed its primary anxiety endpoint.
Key cautions
  • Cannabis use disorder can worsen anxiety and depression outcomes; the packet asks whether use is rising.
  • The packet asks about any personal or family history of psychosis or bipolar disorder, and whether evidence-based therapy has been offered.

7 cited sources · packet refs [3, 4, 50–54]

Depression (regional)

Evidence strength: Little or none

Why it is included
Regional, not named in Ecuador’s rules: 6% of disease answers in Argentina’s RACME/CONICET survey (1,459 responses). No Ecuadorian data on reasons for use were found.
What the research shows
The National Academies (2017) found limited evidence that cannabinoids are ineffective for depressive symptoms in chronic pain or MS. Reviews found scarce or no randomized evidence of benefit for depression, and in a pragmatic trial adults given a medical cannabis card had no improvement in depressive symptoms.
Key cautions
  • The National Academies found moderate evidence of a small increased risk of developing depressive disorders with cannabis use; adolescent use is linked with later depression and suicidal ideation.
  • The packet asks about suicidal thoughts and whether psychotherapy or medication has been offered and documented.

6 cited sources · packet refs [3, 4, 48, 50, 51, 55]

Migraine (regional)

Migraine (regional)

Evidence strength: Some human evidence (one acute trial)

Why it is included
Regional, not named in Ecuador’s rules: 5% of disease answers in Argentina’s RACME/CONICET survey (1,459 responses). No Ecuadorian data on reasons for use were found.
What the research shows
In a 2026 randomized crossover trial (92 participants, 247 attacks), vaporized THC plus CBD beat placebo for pain relief (67.2% vs 46.6%) and pain freedom (34.5% vs 15.5%) at two hours; CBD-dominant cannabis was not better than placebo. Other evidence is observational, and reviews call it promising but low quality.
Key cautions
  • In a case-referent study, medication-overuse headache was more common in cannabis users (adjusted OR 6.3).
  • The packet asks how many days a month acute medication is used.

6 cited sources · packet refs [3, 56–60]

Unranked: the order follows the packet’s sections, not frequency. Source counts are the numbered sources the packet cites in each condition’s section, including Acuerdo Ministerial 00148-2021 [1] for the six named uses or the RACME/CONICET survey [3] for the four regional conditions; the packet lists 67 in total, with PubMed citations verified by PMID in October 2026. The 1% THC threshold in the regulation is stated as law only. These summaries are condensed from the packet. Education only: no doses, product recommendations or drug-interaction verdicts.